Robin Carr, Myricx Bio CEO
In pivot to buzzy ADCs, London biotech Myricx raises $114M with Lilly's support
On the verge of raising its Series A in late 2021, Myricx Bio faced a tough choice.
The toxicity profile for its IV and oral …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
